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Abstract
AIM
To analyze the effect of intralesional steroid injections 
in addition to endoscopic dilation of benign refractory 
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esophageal strictures.
METHODS
A comprehensive search was performed in three data-
bases from inception to 10 April 2017 to identify trials, 
comparing the efficacy of endoscopic dilation to dilation 
combined with intralesional steroid injections. Following 
the data extraction, meta-analytical calculations were 
performed on measures of outcome by the random-
effects method of DerSimonian and Laird. Heterogeneity 
of the studies was tested by Cochrane’s Q  and I 2 
statistics. Risk of quality and bias was assessed by the 
Newcastle Ottawa Scale and JADAD assessment tools.
RESULTS
Eleven articles were identified suitable for analyses, 
involving 343 patients, 235 cases and 229 controls 
in total. Four studies used crossover design with 121 
subjects enrolled. The periodic dilation index (PDI) 
was comparable in 4 studies, where the pooled result 
showed a significant improvement of PDI in the steroid 
group (MD: -1.12 dilation/month, 95%CI: -1.99 to -0.25 
P  = 0.012; I 2 = 74.4%). The total number of repeat 
dilations (TNRD) was comparable in 5 studies and 
showed a non-significant decrease (MD: -1.17, 95%CI: 
-0.24-0.05, P = 0.057; I 2 = 0), while the dysphagia 
score (DS) was comparable in 5 studies and did not 
improve (SMD: 0.35, 95%CI: -0.38, 1.08, P  = 0.351; I 2 
= 83.98%) after intralesional steroid injection.
CONCLUSION
Intralesional steroid injection increases the time be-
tween endoscopic dilations of benign refractory eso-
phageal strictures. However, its potential role needs 
further research.
Key words: Intralesional steroid; Meta-analysis; Benign 
refractory esophageal stricture; Dilation
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Benign refractory stricture can be a very chal-
lenging pathology, which requires regular endoscopic 
dilations. Results of this meta-analysis suggest that 
endoscopic intralesional steroid injection significantly 
decreases the frequency of the endoscopic dilations in 
benign refractory esophageal strictures. In addition, 
there are very few and mild complications reported 
in association with this method. We believe that 
the benefits of intralesional steroid in the treatment 
of benign refractory stricture overweigh its risks. 
However, further research would be essential on this 
treatment method, as there are no data concerning its 
efficacy and safety in different etiologies of refractory 
esophageal strictures.
Szapáry L, Tinusz B, Farkas N, Márta K, Szakó L, Meczker Á, 
Hágendorn R, Bajor J, Vincze Á, Gyöngyi Z, Mikó A, Csupor 
D, Hegyi P, Erőss B. Intralesional steroid is beneficial in benign 
refractory esophageal strictures: A meta-analysis. World J 
Gastroenterol 2018; 24(21): 2311-2319  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v24/i21/2311.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v24.i21.2311
INTRODUCTION
Benign esophageal stricture (BES) is the narrowing of 
the lumen due to scar formation and fibrosis[1]. The 
most common, simple strictures need 3-5 sessions of 
endoscopic dilation at most, while benign refractory 
esophageal strictures (BRES) require more than 
3-5 repeated endoscopic dilation sessions, or it is 
impossible to achieve a 14 mm wide lumen after 3 
sessions of dilation[2]. 
Patients fail to maintain an effective swallowing 
action resulting in significant dysphagia. Other 
symptoms can be atypical chest pain, heartburn and 
odynophagia. BRES significantly impair the quality 
of life and may cause severe complications, most im-
portantly weight loss due to malnutrition, but aspiration 
and regurgitation may occur too[3]. Patients with 
BRES need regular endoscopic dilations and it is not 
uncommon that the stricture recurs in days or weeks, 
necessitating frequent repeat procedures, in some 
cases multiple times a month.
There are many potential causes of BRES, the most 
frequent being peptic stricture from pathological acid 
exposure in gastro-esophageal reflux disease (GERD). 
Other common causes include radiation, caustic 
injury, and anastomotic strictures after esophageal 
surgery or endoscopic submucosal dissection. Less 
frequent etiologies include eosinophilic esophagitis, 
congenital and drug-induced stenosis, and it may also 
develop as a complication of nasogastric intubation or 
sclerotherapy of esophageal varices[1].
The pathogenesis of BRES is not entirely under-
stood, but chronic inflammation must have a key role. 
The initial narrowing of the esophageal wall results from 
edema and muscular spasm as part of an inflammatory 
process. As the disease progresses, erosions and 
ulcerations evolve as well as chronic inflammation, 
leading to fibrous tissue production and collagen 
deposition. The chronic inflammation probably induces 
the synthesis of transforming growth factor beta 
(TGF-β) and α2-macroglobulin, which are inhibitors of 
collagenase activity. Therefore, depositions of collagen 
form scars, resulting in the narrowing of the lumen 
and the rigidity of the wall[3]. Steroids (triamcinolone 
acetonide injection into 4 quadrants of the stricture[2]) 
reduce the activity of these inflammatory pathological 
pathways (e.g. the transcription of matrix protein 
genes, including fibronectin and procollagen), so this 
may be considered as an effective treatment of scar-
forming conditions, providing the basis for the trials 
included in this meta-analysis[1].
The epidemiology of BRES is not well-known. Most 
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of the available data are provided by small clinical 
studies and case studies. The incidence of esophageal 
stricture seems to be decreasing in parallel with the 
growing use of proton pump inhibitors (PPIs)[3,4], yet 
its common cause is GERD and it still occurs in 7%-23% 
of GERD patients with esophagitis[4].
Endoscopic dilation is an effective standard treat-
ment for BES[1,2]; however, 30%-40% of patients 
show refractory dysphagia within the first year after 
intervention and require frequent and repeat dilations in 
the long term[3]. Several trials have been conducted to 
determine the efficacy of intralesional steroid injection 
in the treatment of BRES since the first encouraging 
results were published in a canine model in 1969[5]. 
However, a meta-analysis has not been carried out yet.
We wanted to investigate whether intralesional 
steroid injection in combination with dilation is bene-
ficial in the treatment of BRES.
MATERIALS AND METHODS
A meta-analysis was performed following the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement[6]. The meta-analysis 
was registered in advance in PROSPERO under the 
registration number 42017072329. The PICO items 
of the search strategy were: Population (P): Patients 
with esophageal stricture; intervention (I): Dilation plus 
intralesional steroid injection; control (C): Dilation alone; 
and outcomes (O): Dysphagia score (DS), total number 
of repeat dilations (TNRD) and periodic dilation index 
(PDI).
Search strategy
The article search was carried out in PubMed, Embase 
and Cochrane databases from inception to 10 April 
2017. Two investigators conducted a comprehensive 
search with a combination of the following keywords: 
(oesophagus OR esophagus) AND [stricture OR ste-
nosis OR refractory stricture OR benign stricture OR 
(o)esophageal stricture] AND (dilation OR dilatation) 
and (steroid OR triamcinolone OR intralesional ste-
roid). No filters were imposed on the searches in 
the individual databases. References in the primarily 
eligible articles were screened for additional suitable 
publications.
Inclusion and exclusion criteria: Articles were 
selected if they had detailed data on a control (endo-
scopic dilation only) and a treatment group (endoscopic 
dilations with intralesional steroid injection). Benign 
refractory esophageal strictures of all etiologies re-
quiring repeat dilations were included. Language was 
not an exclusion criterion. Conference abstracts were 
also included if they contained sufficient data. Case 
reports, case series, and results from pediatric and 
non-human trials were excluded. We did not contact 
the authors of the included articles.
Selection process: Records were managed by 
the EndNote X7.4 software (Clarivate Analytics, 
Philadelphia, PA, United States) to remove duplicates. 
Publications were screened first by title, second by 
abstract, and finally by full-text, based on our eligibility 
criteria. The comprehensive search and the selection 
of the studies were carried out by two investigators. 
Data extraction
Numeric and texted data were extracted onto a purpose 
designed Excel 2016 sheet (Office 365, Microsoft, 
Redmond, WA, United States). The extracted data 
were the following: study author, year of publication, 
geographical location, study design, number of con-
trols and cases, age of the patients, etiology of the 
strictures, length and location of the stricture, dose 
of the intralesional steroid injection, the outcomes of 
the treatment with and without intralesional steroid 
injection (DS, TNRD and PDI, the complications of the 
treatment and follow-up time). Data extraction was 
performed by two investigators and extracted data 
were checked by a third investigator.
Statistical analysis
In our statistical analysis, we compared the outcomes 
of treatment with dilation alone to the outcomes of 
dilation in combination with intralesional steroid in-
jections. Meta-analytical calculations were conducted 
on the TNRD, PDI and DS. Standardized difference 
in means (SMD), difference in means (MD) and 95% 
confidence interval (95%CI) were calculated using the 
random-effects method developed by DerSimonian and 
Laird[7]. Results reported in the study in median and 
range were converted to means and standard deviation 
with the Hozo method[8]. Heterogeneity among trials 
was tested with Cochrane’s Q and I2 statistics. According 
to the Cochrane Handbook, I2 values of 25%-50%, 
50%-75% and > 75% correspond to low, moderate 
and high degrees of heterogeneity[9]. The Q test implies 
that the heterogeneity among effect sizes reported in 
the studies under examination is more diverse than 
could be explained by random error only. We considered 
the Q test significant if P < 0.1. The presence of any 
publication bias was examined by visual inspection of 
the funnel plots.
Assessment of risk of selection and information bias
The assessment of risks of bias and quality was done at 
the outcome level. The Newcastle-Ottawa Scale[10] was 
used for case control trials with the following 8 items. 
Item 1: Were the cases randomly selected subjects 
with BRES without significant exclusion criteria? Item 2: 
Were the controls randomly selected subjects with BRES 
without significant exclusion criteria? Item 3: Was there 
an endoscopic or radiological diagnosis of BRES? Item 
4: Was the diagnosis of non-refractory BES excluded? 
Item 5: Were the cases and controls comparable? Item 
2313 June 7, 2018|Volume 24|Issue 21|WJG|www.wjgnet.com
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selection process is shown on Figure 1 and the main 
characteristics of the studies included are shown in 
Table 1.
Results of the statistical analysis
The PDI was comparable in 4 studies with crossover 
design involving 121 patients[13,14,15,16]. The pooled 
result showed that PDI significantly decreased in the 
intralesional steroid plus dilation group, with difference in 
means method. (MD: -1.16, 95%CI: -1.99, -0.25, P = 
0.012). There was a high degree of heterogeneity across 
the studies included in the analysis for PDI (Q = 11.73, 
df = 3, P = 0.0084, I2 = 74.43%). A detailed result of the 
analysis on PDI by the random effect model is shown in 
Figure 2.
The TNRD was comparable in 5 studies[17,18,19,20,21], 
where MD was -1.172 in comparison to the dilation 
alone group (95%CI: -0.238, 0.053; P = 0.057). The 
studies in this analysis showed no heterogeneity: (Q = 
3.66; df = 4; P = 0.45; I2 = 0.0%). A detailed result 
of the analysis on TNRD by the random effect model is 
shown in Figure 3.
The DS was comparable in 5 studies[17,18,21,22,23], and 
an improvement could not be observed in the combined 
therapy group (std. MD: 0.347, 95%CI: -0.383, 1.077, 
P = 0.351). We note that DS was only comparable with 
standardization as different studies used different scoring 
systems. There was a high degree of heterogeneity 
across the studies included in the analysis for DS (Q = 
24.97, df = 4, P < 0.001, I2 = 83.98%). A detailed result 
of the analysis on DS by the random effect model is 
shown in Figure 4. 
Complications
Due to the low number of events of complications, 
statistical analysis was not possible; therefore, only 
narrative synthesis could be performed. It is important 
to note that all trials reported low numbers of com-
plications; therefore, this technique seems to be 
safe. Kochhar et al[13] reported transient worsening of 
dysphagia for 24 h in one patient after the intralesional 
6: Were the subjects and investigators blinded to the 
intralesional steroid treatment? Item 7: Was follow-up 
long enough (≥ 6 mo) for outcomes to occur? Item 8: 
Was there complete follow up of all subjects enrolled? 
For the above detailed items an answer of yes re-
presented low risk, no represented high risk, while 
lack of description represented unknown risk of bias. 
Modified NOS was used for studies with cross-over 
study design with the 7 out of the above detailed 8 
items as item 2 regarding the selection of controls was 
not applicable due to the cross-over study design. 
The JADAD scoring system[11] was used for the 
assessment of randomized controlled trials with the 
following 5 items. Item 1: Was the study described 
as randomized? (Yes = 1 point, No = 0 point); Item 
2: Was the randomization scheme described and ap-
propriate? (Yes = 1 point, No = -1 point); Item 3: Was 
the study described as double-blind? (Yes = 1 point, 
No = 0 point); Item 4: Was the method of double 
blinding appropriate? (Yes = 1 point, No = -1 point, if 
the answer of Item 3 was No, Item 4 is not calculable); 
Item 5: Was there a description of dropouts and 
withdrawals? (Yes = 1 point, No = 0 point).
Assessment of the grade of evidence
The GRADE system was used to assess the strength 
of recommendation and quality of evidence of our 
results. GRADE stands for Grades of Recommendation 
Assessment, Development, and Evaluation[12].
RESULTS
Results of the selection process
Our search identified 321 articles in Embase, 109 in 
PubMed, and 12 in the Cochrane database, a total of 
11 articles[13-23] (10 in English and 1 in Portuguese) 
eligible for the quantitative analysis, these included 
343 patients in total, 235 cases and 229 controls, as 
four studies used cross-over design with 121 subjects 
enrolled. Further 3 articles gave results, but they were 
not suitable for meta-analytical calculations[24-26]. The 
Study Study design Country Parameter Patients Etiology of 
BRES
Follow-up 
(mo)
Complication
Cases Control Cases Control
Kochhar et al[13] 1999 Crossover India PDI 14 14 Mixed 23 1 0
Kochhar et al[14] 2002 Crossover India PDI 71 71 Mixed 59 0 0
Ahn et al[16] 2015 Crossover New Zealand PDI 25 25 Mixed 90 0 0
Nijhawan et al[16] 2016 Crossover India PDI 11 11 Corrosive 18 0 0
Dunne et al[17] 1999 RCT United States TNRD, DS 20 22 Mixed 60 0 0
Altintas et al[18] 2004 RCT Turkey TNRD 11 10 Mixed 48 1 1
Orive-Calzada et al[20] 2012 Cohort Spain TNRD 14   9 Mixed 45 0 1
Hirdes et al[19] 2013 RCT Netherland TNRD, DS 31 29 Anastomotic 33 5 1
Pereira-Lima et al[21] 2015 RCT Brazil TNRD, DS   9 10 Mixed 13 0 0
Camargo et al[22] 2003 RCT Brazil DS   7   7 Mixed 12 0 0
Rupp et al[23] 1995 RCT United States DS 22 21 Mixed 11 0 0
Table 1  Main characteristics of the studies included
PDI: Periodic dilation index; NRD: Total number of repeat dilations; DS: Dysphagia score; RCT: Randomized controlled trial; BRES: Benign refractory 
esophageal stricture.
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steroid injection. There were 2 perforations reported by 
Altintas et al[18] one in the dilation only and one in the 
combined treatment group, both in caustic strictures. 
Hirdes et al[19] reported one gastrointestinal bleeding in 
the monotherapy group and 5 adverse events, such as 
1 laceration and 4 candida esophagitis in the patients 
treated with intralesional steroid. However, the laceration 
developed in a patient, who continued the anticoagulant 
therapy during the procedure, and the other 4 patients 
received adjuvant chemotherapy, which is a risk factor for 
candidiasis. One perforation occurred in the dilation only 
group in Orive-Calzada et al[20] trial, with no complication 
reported in patients with intralesional steroid injection. 
Other trials did not report any adverse events in either 
therapy group.
Results of the assessment of risk of bias and quality
Detailed results of the assessments are shown in Table 
2 and 3. 
DISCUSSION
The summary of our findings are shown in Table 4. 
Endoscopic dilation as the standard treatment of BES is 
effective in most cases[1,2], but BRES develops in some 
cases, necessitating repeated endoscopic dilations in the 
long term[3]. Endoscopic intralesional steroid injections 
may be useful and may reduce the number of necessary 
dilations. However, because of the low incidence of 
refractory benign esophageal strictures and because of 
the low number of studies and articles published on the 
Figure 1  Prisma flow chart of the study selection process.
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8
Ahn et al[21] 2015 - N/A + + - ? + ? Modified NOS
Kochhar et al[21] 2015 - N/A + + - ? + + Modified NOS
Kochhar et al[21] 2015 + N/A + + - ? + + Modified NOS
Nijhawan et al[21] 2015 - N/A + + - - + + Modified NOS
Orive-Calza et al[21] 2015 - - + ? + + + ? NOS
Item 1: Were the cases randomly selected subjects with BRES without significant exclusion criteria? Item 2: Were the controls randomly selected subjects 
with BRES without significant exclusion criteria? Item 3: Was there an endoscopic or radiological diagnosis of BRES? Item 4: Was the diagnosis of non-
refractory BES excluded? Item 5: Were the cases and controls comparable? Item 6: Were the subjects and investigators blinded to the intralesional steroid 
treatment? Item 7: Was follow-up long enough (≥ 6 mo) for outcomes to occur? Item 8: Was there complete follow up of all subjects enrolled? For the above 
detailed items an answer of yes represented low risk, no represented high risk, while lack of description represented unknown risk of bias (- = high risk of 
bias; ? = unknown or moderate risk of bias; + = low risk of bias). BRES: Benign refractory esophageal stricture; BES: Benign esophageal stricture.
Table 2  Results of the Newcastle-Ottawa quality assessment scale for cross-over and cohort studies
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Records identified through 
database searching
(n  = 442)
Additional records identified 
through other sources
(n  = 6)
Records after duplicates removed
(n  = 339)
Records screened
(n  = 339)
Full-text articles assessed 
for eligibility
(n  = 44)
Studies included in 
qualitative synthesis
(n  = 14)
Studies included in quantitative 
synthesis (meta-analysis)
(n  = 11)
Records excluded
(n  = 295)
Full-text articles excluded, 
with reasons
(n  = 29)
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topic, there is little evidence as to whether this approach 
is beneficial. Moreover, to the best of our knowledge, no 
meta-analysis has been carried out yet.
The effectiveness of intralesional steroid injections for 
BRES was first tested in a canine model in 1969[7]. The 
first study on humans was carried out by Holder et al[27]. 
They examined 10 pediatric patients, some with post-
surgical (anastomotic) strictures and some with corrosive 
strictures (from acid or lye). They found that additional 
intralesional steroid treatments were only effective on 
the anastomotic strictures, but not on the caustic ones.
Among the parameters of the 11 articles included 
in our meta-analysis, the PDI, TNRD and DS were com-
parable. It is important to note that all studies used 
boogie dilators and no studies reported results with 
balloon dilation
The PDI values were calculated with the mean 
difference method due to the similar measures and 
showed a significant improvement of the PDI in the 
steroid group. These four articles[13-16] examined one 
patient group, treated first with a series of dilations 
alone, followed by a dilation combined with intralesional 
steroid injections afterwards. PDI values were 
compared before and after the intralesional steroid 
injections, as these patients all required continuing 
endoscopic dilation despite the steroid injections. It 
Item 1 Item 2 Item 3 Item 4 Item 5 Overall Quality
Dunne et al[17] 1999 1 -1 0  0 0 0 Low; 0
Altintas et al[18] 2004 1 -1 0  0 0 0 Low; 0
Hirdes et al[19] 2013 1  1 1  1 1 5 High; 5
Pereira-Lima et al[21] 2015 1  1 1  1 1 5 High ,5
Camargo et al[21] 2003 1 -1 1 -1 1 1 Low; 1
Rupp et al[21] 1995 1 -1 0  0 0 0 Low; 0
Item 1: Was the study described as randomized? (Yes = 1 point, No = 0 point); Item 2: Was the randomization scheme described and appropriate? (Yes 
= 1 point, No = -1 point); Item 3: Was the study described as double-blind? (Yes = 1 point, No = 0 point); Item 4: Was the method of double blinding 
appropriate? (Yes = 1 point, No = -1 point, if the answer of Item 3 was No, Item 4 is not calculable); Item 5: Was there a description of dropouts and 
withdrawals? (Yes = 1 point, No = 0 point). Low range of quality: 3 >, high range of quality: 2 <.
Table 3  Results of the quality assessment of randomized controlled trials by the JADAD scoring system
Table 4  Summary of findings
Outcomes Intervention values Control values Number of patients Quality of evidence (GRADE) Comments
PDI 0.335/mo 1.355/mo 121 Very low Only studies with cross-over 
design were analyzedMD: -1.12 
95%CI: -1.99 to -0.25 
P = 0.012
TNRD n/a n/a 165 Very low Different length of follow up 
results in high risk of biasMD: -1.17
 95%CI: -0.24 to 0.05
P = 0.057
DS n/a n/a 178 Very low Different scoring scales were 
used and different lengths of 
follow up result in high risk 
of bias
SMD: 0.35
95%CI: -0.38 to 1.08
P = 0.351
PDI: Periodic dilation index; TNRD: Total number of repeat dilations; DS: Dysphagia score; MD: Mean difference; SMD: Standardized mean difference.
Figure 2  Forest plot of the random effect analysis of the 4 studies concerning periodic dilation index shows a significant decrease of periodic dilation 
index after intralesional steroid injection in addition to endoscopic dilation.
Study name Statistics for each study
Difference 
in means
Standard 
error
Lower 
limit
Upper 
limit
P -value
Kochar, 1999 -1.440 0.478 -2.377 -0.503 -0.003
Kochar, 2002 -0.740 0.371 -1.467 -0.013 0.046
Ahn, 2015 -0.300 0.075 -0.446 -0.154 0.000
Nijhawan, 2015 -2.350 0.512 -3.354 -1.346 0.000
-1.115 0.444 -1.985 -0.245 0.012
Difference in means and 95%CI
-4.00    -2.00    0.00    2.00    4.00
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must be noted that the study by Nijhawan et al[15] 
showed a statistically significant, strong improvement 
in the PDI with the combined therapy in patients 
with corrosive strictures only, so the lack of subgroup 
analysis results in a high degree of bias.
The TNRD[17,18,19,20,21] was compared with the method 
noted above. We found a non-significant (P = 0.057) 
improvement in the combined therapy group using 
the mean difference method. Interestingly, the article 
by Orive-Calazda et al[20] did not identify improvement 
compared to the control groups: 9 study group patients 
and 12 control group patients received 30 and 37 
dilations, respectively. The only published multicenter 
study investigating the TNRD was carried out by 
Hirdes et al[19], but all the patients had an anastomotic 
stricture, resulting in a bias in the interpretation of their 
data. In this case, the importance of the subgroup 
analysis must be highlighted again.
The third parameter, which describes the quality 
of life best, is the DS. Due to the use of different 
scoring systems, it was only possible to compare the 
data from five articles[17,19,21,22,23] with standardization. 
Based on the statistical analysis of the articles under 
examination, we did not find any improvement in the 
steroid group. However, this result cannot be regarded 
as relevant due to the high heterogeneity of the data. 
It is important to note that Pereira-Lima et al[21], proved 
a significant improvement in the DS in the combined 
therapy group in a randomized controlled trial. Hirdes 
et al[19] reported DS results in patients with anastomotic 
strictures only, which remains a significant bias. 
Only a few studies reported outcomes of the treat-
ment with intralesional steroids for different etiologies 
of the strictures. Kochhar et al[13] and Nijhawan et al[15] 
demonstrated significant improvement in caustic 
strictures. Hirdes et al[19] detected no benefit from 
the combined treatment in anastomotic stricures. 
Ahn et al[16]and Kochhar et al[14] showed the most 
improvement in peptic strictures, both in studies with 
cross over design. 
There was no data on the histological activity of the 
inflammation of the strictures, although intralesional 
steroid is likely to be of more benefit in strictures 
with high degree of active inflammation, than in long 
standing fibrotic strictures. Subgroup analysis on the 
degree of inflammation could have given further in 
depth understanding of the effects of intralesional 
steroid injections.
Limitations
We observed variable reporting of intervention outcomes. 
Studies with low patient numbers, heterogeneous data, 
Study name Statistics for each study
Difference 
in means
Standard 
error
Lower 
limit
Upper 
limit
P -value
Dunne et al. , 1995 -3.550 1.381 -6.257 -0.843 0.010
Altintas et al. , 2004 -0.700 1.173 -2.998 1.598 0.551
Orive-Calzada et al. , 2012 0.330 0.776 -1.192 1.852 0.671
Hirdes et al. , 2013 -2.000 0.940 -3.842 -0.158 0.033
Pereira-Lima et al. ,2014 -1.000 0.919 -2.801 0.801 0.277
-1.172 0.617 -2.381 0.037 0.057
Difference in means and 95%CI
-7.00      -3.50     0.00      3.50      7.00
Figure 3  Forest plot of the random effect analysis of the 5 studies concerning total number of repeat dilation shows a non-significant decrease of total 
number of repeat dilation after intralesional steroid injection in addition to endoscopic dilation.
Study name Statistics for each study
Std diff in 
means
Standard 
error
Lower 
limit
Upper 
limit
P -value
Dunne et al. , 1995 0.674 0.318 0.052 1.297 0.034
Rupp et al. , 1995 1.081 0.327 0.441 1.721 0.001
Camargo et al. , 2007 1.165 0.578 0.032 2.298 0.044
Hirdes et al. , 2013 0.072 0.258 -0.434 0.579 0.779
Pereira-Lima et al. ,2014 -1.354 0.509 -2.353 -0.356 0.008
0.347 0.372 -0.383 1.077 0.351
Std diff in means and 95%CI
-4.00  -2.00  0.00  2.00  4.00
Figure 4  Forest plot of the random effect analysis of the 5 studies concerning dysphagia score shows no significant improvement of dysphagia score 
after intralesional steroid injection in addition to endoscopic dilation.
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use of different scoring systems, and differences in 
follow-up time resulted in significant difficulties of 
the analysis. Even though two long-term studies[17,23] 
were only available as abstracts, they contained 
the necessary data for the purposes of this meta-
analysis. In addition, there was a lack of detailed data 
on etiological subgroups, which prevented us from 
performing a subgroup analysis, reulting in a high risk 
of bias. 
In summary, the use of intralesional steroid in-
jections seems to be beneficial in the treatment of 
BRES with a very low quality of evidence and a weak 
recommendation. A large, multicenter, prospective 
randomized trial could provide better evidence for the 
role of intralesional steroid therapy in the treatment of 
BRES. 
ARTICLE HIGHLIGHTS
Research background
Benign refractory esophageal stricture deteriorates the quality of life, as 
impaired and often painful swallowing necessitates semi liquid or liquid diet and 
leads to poor nutrition. Regular endoscopic dilations are a huge burden to the 
patients, carry risks of complications, require special expertise, and accessories 
of the endoscopy unit. 
Research motivation
Our aim was to investigate if there is any benefit of intralesional steroid injection 
in addition to endoscopic dilation in the treatment of refractory esophageal 
strictures.
Research objectives 
This is the first comprehensive article in this topic, taking into account all the 
available evidences and this study quantifies the effect of intralesional steroid 
injection in addition to endoscopic dilation of benign refractory esophageal 
stricture.
Research methods
A meta-analysis was performed following the guidelines of the PRISMA P 
protocol and the review was registered on PROPSPERO. PubMed, Cochrane 
Library and Embase databases were comprehensively searched for trials 
eligible for the analysis, describing the outcomes of dilation in comparison to 
dilation with intralesional steroids. The risks of bias and quality of the individual 
studies were assessed by using the Newcastle-Ottawa Scale and JADAD 
Score. The random effect model described by DerSimonian-Laird was used to 
perform the statistical calculations.
Research results
The statistical analysis involved 343 patients with benign refractory stricture. 
The results showed that intralesional steroid significantly increased the time 
between endoscopic dilations, from 1.3-0.3 dilations/month. However, the 
dysphagia score and the total number of dilation did not improve. 
Research conclusions
Intralesional steroid injection increases the time between endoscopic dilations 
of benign refractory esophageal strictures. 
Research perspectives
Further research would be essential to understand the effects of intralesional 
steroid injection in the treatment of benign refractory esophageal strictures. A 
multi-center, double blind, randomized controlled trial could give better answers. 
Detailed data on the outcomes of the treatment in view of the etiology, the time 
of the diagnosis, the degree of inflammation/fibrosis, the length and location of 
the stricture should be collected with a long follow up period.
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